Papillon‐Lefèvre syndrome: Oral aspects and treatment

Abstract

Papillon‐Lefèvre syndrome (PLS) is a rare disorder characterized by diffuse palmoplantar erythematous, fissured hyperkeratosis, and aggressive periodontal disease that starts in the early periods of childhood. Periodontal disease occurs with the early loss of deciduous teeth at the age of 2 to 4 years, followed by the loss of permanent teeth during adolescence. Prosthodontics management of PLS patients is very complex and sometimes requires invasive therapeutic treatments. Early diagnosis is essential for correct treatment management avoiding the possibility that patients are early edentulous. Management could be a conventional periodontal treatment and pharmacological therapy but in severe cases, digital techniques, could be help the clinician for increased patient comfort and minimized tissue damage.

Dental Prosthetic Rehabilitation of Papillon-Lefèvre Syndrome: A Case Report

“…Sometimes, root completion might be incomplete and microdontia might be found in a few PLS cases, however it was not reported in the present case. 13 Primary loss of alveolar bone around the teeth causes loss of teeth resulting in edentulism. Gingiva reverts to normal health after exfoliation of teeth.…”

“…Some clinicians propose the usage of digital technologies in psychologically traumatized PLS patients, wherein, extraction and denture delivery is performed on the very same day. 13 Computer-supported technologies and machinery make this step possible. Prosthetic rehabilitation provides a psychological boost up to the patient by restoring function and esthetic appearance.…”

Recurrent Aphthous Stomatitis: Treatment and Management

“…Recurrent aphthous stomatitis (RAS) [1], is a common oral disease characterized by multiple, small, round or oval mucosal ulcers with circumscribed margins, erythematous haloes, and yellow or gray floors that initially appear during childhood or adolescence. Many diseases [3][4][5][6][7][8][9][10] that affect the oral cavity can have similar clinical presentations, making correct diagnosis difficult and sometimes delaying therapy. Unfortunately, the etiology of RAS of is still unknown.…”

Therapy of autoimmune mouth bullous disease: 2020 review

“…The treatment of pemphigus is historically based essentially on the administration of corticosteroids (CS) and immunosuppressive drugs (conventional therapies) and adjunctive or alternative therapies. [25][26][27][28][29][30] The advent of rituximab (RTX), the monoclonal IgG antibody against CD20, has revolutionized the treatment of pemphigus indicating that a complete remission off therapy is possible.…”